FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897549435> ?p ?o ?g. }

• W2897549435 endingPage "S11" @default.
• W2897549435 startingPage "S10" @default.
• W2897549435 abstract "For patients with early-stage NSCLC, SBRT generally yields favorable local tumor control, but regional and distant failures occur in up to 20-30% of patients. Although adjuvant systemic therapy (ST) is often recommended for early-stage NSCLC with large tumors after surgery, there is a lack of evidence supporting the use of ST with SBRT. We used a multi-institutional database to evaluate the association between ST use and disease and survival outcomes for patients with early-stage NSCLC treated with SBRT. We conducted a retrospective cohort study using a multi-institutional, academic-community practice database, including consecutive patients with biopsy-proven T1-3N0M0 NSCLC treated with definitive SBRT from 2006 – 2015 at 114 sites. Patient cohorts were defined as those who received SBRT+ST or SBRT alone. Group characteristics were compared with Chi-square, Wilcoxon rank-sum, and logistic regression. Local, regional, and distant failure (LF, RF, and DF) were analyzed with multivariable competing risks regression with Fine and Gray’s proportional subhazard models. Progression-free and overall survival were analyzed with the Kaplan-Meier method and Cox regression. Competing risks regression was performed with 2:1 nearest-neighbor propensity score matching on clinical risk factors. Of 1,328 patients included, 54 (4.1%) received SBRT+ST. The most common ST regimen was a platinum doublet (n=38; 70.4%), followed by erlotinib (n=8; 14.8%), single agent chemotherapy (n=3; 5.6%), or unknown regimen (n=5; 9.3%). Compared with SBRT patients, SBRT+ST patients were younger (median age: 71 vs 78, P < 0.001), had larger tumors (>2 cm: 38.9% vs 21.5%, P = 0.003), and higher T-stage (T2-3: 42.6% vs 22.4%, P = 0.001). Median follow-up in living patients was 24 months. Compared with the SBRT cohort, the SBRT+ST cohort had significantly less DF (3.7% vs 13.0%, P = 0.04) and RF (0% vs 10.4%, P = 0.01), but not LF (7.4% vs 10.4%, P = 0.48). On multivariable analyses, SBRT+ST was independently associated with reduced DF (HR: 0.22, 95% CI: 0.05 - 0.88, P = 0.03) and overall failure (HR: 0.34, 95% CI: 0.15 - 0.76, P = 0.009) (RF not evaluable, as there were no events in the SBRT+ST cohort), with trend for improved progression-free (HR: 0.72, 95% CI: 0.49 – 1.06, P = 0.09), but not overall survival (HR: 0.78, 95% CI: 0.52 – 1.18, P = 0.24). After propensity score matching on size, T-stage, performance and smoking status, histology, and age, the SBRT+ST cohort had reduced DF, RF, and overall failure (each P < 0.05). This multi-institutional study shows improved regional, distant, and overall disease control in patients receiving adjuvant systemic therapy with SBRT for early stage NSCLC, despite the increased prevalence of larger and higher-stage tumors in this cohort. Prospective study is being planned to evaluate this hypothesis in high-risk subgroups." @default.
• W2897549435 created "2018-10-26" @default.
• W2897549435 creator A5006355506 @default.
• W2897549435 creator A5009275122 @default.
• W2897549435 creator A5018154366 @default.
• W2897549435 creator A5018495020 @default.
• W2897549435 creator A5032179145 @default.
• W2897549435 creator A5052126628 @default.
• W2897549435 creator A5062661940 @default.
• W2897549435 creator A5063184651 @default.
• W2897549435 creator A5071827540 @default.
• W2897549435 creator A5078289544 @default.
• W2897549435 date "2018-11-01" @default.
• W2897549435 modified "2023-10-16" @default.
• W2897549435 title "Systemic Therapy with Stereotactic Body Radiation Therapy (SBRT) for Early-Stage Non-Small Cell Lung Carcinoma (NSCLC): A Multi-institutional Analysis" @default.
• W2897549435 doi "https://doi.org/10.1016/j.ijrobp.2018.06.119" @default.
• W2897549435 hasPublicationYear "2018" @default.
• W2897549435 type Work @default.
• W2897549435 sameAs 2897549435 @default.
• W2897549435 citedByCount "0" @default.
• W2897549435 crossrefType "journal-article" @default.
• W2897549435 hasAuthorship W2897549435A5006355506 @default.
• W2897549435 hasAuthorship W2897549435A5009275122 @default.
• W2897549435 hasAuthorship W2897549435A5018154366 @default.
• W2897549435 hasAuthorship W2897549435A5018495020 @default.
• W2897549435 hasAuthorship W2897549435A5032179145 @default.
• W2897549435 hasAuthorship W2897549435A5052126628 @default.
• W2897549435 hasAuthorship W2897549435A5062661940 @default.
• W2897549435 hasAuthorship W2897549435A5063184651 @default.
• W2897549435 hasAuthorship W2897549435A5071827540 @default.
• W2897549435 hasAuthorship W2897549435A5078289544 @default.
• W2897549435 hasConcept C121608353 @default.
• W2897549435 hasConcept C126322002 @default.
• W2897549435 hasConcept C126838900 @default.
• W2897549435 hasConcept C143998085 @default.
• W2897549435 hasConcept C146357865 @default.
• W2897549435 hasConcept C151730666 @default.
• W2897549435 hasConcept C151956035 @default.
• W2897549435 hasConcept C167135981 @default.
• W2897549435 hasConcept C17923572 @default.
• W2897549435 hasConcept C185926286 @default.
• W2897549435 hasConcept C2781413609 @default.
• W2897549435 hasConcept C50382708 @default.
• W2897549435 hasConcept C530470458 @default.
• W2897549435 hasConcept C71924100 @default.
• W2897549435 hasConcept C72563966 @default.
• W2897549435 hasConcept C86803240 @default.
• W2897549435 hasConceptScore W2897549435C121608353 @default.
• W2897549435 hasConceptScore W2897549435C126322002 @default.
• W2897549435 hasConceptScore W2897549435C126838900 @default.
• W2897549435 hasConceptScore W2897549435C143998085 @default.
• W2897549435 hasConceptScore W2897549435C146357865 @default.
• W2897549435 hasConceptScore W2897549435C151730666 @default.
• W2897549435 hasConceptScore W2897549435C151956035 @default.
• W2897549435 hasConceptScore W2897549435C167135981 @default.
• W2897549435 hasConceptScore W2897549435C17923572 @default.
• W2897549435 hasConceptScore W2897549435C185926286 @default.
• W2897549435 hasConceptScore W2897549435C2781413609 @default.
• W2897549435 hasConceptScore W2897549435C50382708 @default.
• W2897549435 hasConceptScore W2897549435C530470458 @default.
• W2897549435 hasConceptScore W2897549435C71924100 @default.
• W2897549435 hasConceptScore W2897549435C72563966 @default.
• W2897549435 hasConceptScore W2897549435C86803240 @default.
• W2897549435 hasIssue "3" @default.
• W2897549435 hasLocation W28975494351 @default.
• W2897549435 hasOpenAccess W2897549435 @default.
• W2897549435 hasPrimaryLocation W28975494351 @default.
• W2897549435 hasRelatedWork W2891061311 @default.
• W2897549435 hasRelatedWork W2906178231 @default.
• W2897549435 hasRelatedWork W2963045567 @default.
• W2897549435 hasRelatedWork W2980864243 @default.
• W2897549435 hasRelatedWork W2989672665 @default.
• W2897549435 hasRelatedWork W2989808867 @default.
• W2897549435 hasRelatedWork W3007385212 @default.
• W2897549435 hasRelatedWork W4213445964 @default.
• W2897549435 hasRelatedWork W4235834539 @default.
• W2897549435 hasRelatedWork W4304808194 @default.
• W2897549435 hasVolume "102" @default.
• W2897549435 isParatext "false" @default.
• W2897549435 isRetracted "false" @default.
• W2897549435 magId "2897549435" @default.
• W2897549435 workType "article" @default.